Publication Name	World Journal of Clinical Oncology
Manuscript ID	59435
Country	Spain

Received	2020-09-10 12:00
Peer-Review Started	2020-09-10 12:00
To Make the First Decision
Return for Revision	2020-11-16 21:54
Revised	2020-12-01 09:29
Second Decision	2020-12-10 11:34
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2020-12-14 04:51
Articles in Press	2020-12-14 04:51
Publication Fee Transferred
Edit the Manuscript by Language Editor	2020-12-21 00:47
Typeset the Manuscript	2021-01-15 02:35
Publish the Manuscript Online	2021-01-17 11:30

ISSN	2218-4333 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Editorial
Article Title	Nonmetastatic castration-resistant prostate cancer: Novel agents to treat a lethal disease
Manuscript Source	Invited Manuscript
All Author List	Ivan Henriquez, Daniel Spratt, Alfonso Gómez-Iturriaga, Oscar Abuchaibe and Felipe Couñago
Funding Agency and Grant Number
Corresponding Author	Ivan Henriquez, MD, PhD, Academic Research, Doctor, Medical Assistant, Department of Radiation Oncology, Hospital Universitario Sant Joan, Instituto Investigación Pere i Virgili, Av. Josep Laporte 2, Reus 43204, Tarragona, Spain. ivanhenriquezlopez@me.com
Key Words	Nonmetastatic castration-resistant prostate cancer; Prostate cancer; Apalutamide; Enzalutamide; Darolutamide; Toxicity
Core Tip	The main focus of this editorial is to review novel treatments for nonmetastatic castration-resistant prostate cancer (nmCRPC). The three-practice changing pivotal randomized controlled trials - PROSPER, SPARTAN, and ARAMIS - are reviewed. We discuss the findings of these trials, emphasizing the strengths of the studies, and critically examining controversies related to the diagnosis of nmCRPC and the role of advanced imaging techniques and molecular determinants.
Publish Date	2021-01-17 11:30
Citation	Henriquez I, Spratt D, Gómez-Iturriaga A, Abuchaibe O, Couñago F. Nonmetastatic castration-resistant prostate cancer: Novel agents to treat a lethal disease. World J Clin Oncol 2021; 12(1): 6-12
URL	https://www.wjgnet.com/2218-4333/full/v12/i1/6.htm
DOI	https://dx.doi.org/10.5306/wjco.v12.i1.6

Full Article (PDF)	WJCO-12-6.pdf
Full Article (Word)	WJCO-12-6.docx
Manuscript File	59435-Review-Filipodiav1CL.docx
Answering Reviewers	59435-Answering reviewers.pdf
Audio Core Tip	59435-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	59435-Conflict-of-interest statement.pdf
Copyright License Agreement	59435-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	59435-Language certificate.pdf
Peer-review Report	59435-Peer-review(s).pdf
Scientific Misconduct Check	59435-Scientific misconduct check.pdf
Scientific Editor Work List	59435-Scientific editor work list.pdf